Journal ArticleDOI
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
Raluca Pais,Frédéric Charlotte,Larissa Fedchuk,Pierre Bedossa,Pascal Lebray,Thierry Poynard,Vlad Ratziu +6 more
TLDR
A substantial proportion of patients with NAFL can progress towards well-defined NASH with bridging fibrosis, especially if metabolic risk factors deteriorate, and current monitoring practices of these patients should be revised.About:
This article is published in Journal of Hepatology.The article was published on 2013-09-01. It has received 417 citations till now. The article focuses on the topics: Fatty liver & Steatohepatitis.read more
Citations
More filters
Book ChapterDOI
Clinical Epidemiology of NAFLD
TL;DR: The increasing prevalence of NAFLD with advanced fibrosis is concerning because patients appear to experience higher liver-related and non-liver-related mortality than the general population, and one that requires more in-depth analysis.
Journal ArticleDOI
Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies.
Phuc Le,Julia Y Payne,Lu Zhang,Abhishek Deshpande,Michael B. Rothberg,Naim Alkhouri,William H. Herman,Adrian V. Hernandez,Mary Schleicher,Wenfeng Ye,Srinivasan Dasarathy +10 more
TL;DR: In this paper , the authors conducted a meta-analysis to summarize the rates of progression to and regression of nonalcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and fibrosis in adults with NAFLD. Heterogeneity was assessed using the I2 statistic.
Journal ArticleDOI
Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design.
Pierpaolo Pellicori,Pierpaolo Pellicori,Muthiah Vaduganathan,João Pedro Ferreira,João Pedro Ferreira,Faiez Zannad,Arun J. Sanyal +6 more
TL;DR: In this paper, a framework for consideration for future trials examining the inter-relationship between cardiovascular disease and non-alcoholic fatty liver disease (NAFLD) is provided, and a rationale for considering cardiovascular endpoints in the context of NAFLD trials and, vice-versa, to consider the concomitant presence of NASD in drug development for cardiometabolic disorders.
Journal ArticleDOI
Managing the Burden of Non-NASH NAFLD.
TL;DR: Steatosis without fibrosis carries a low risk of progression to cirrhosis but likely confers an increased risk of diabetes mellitus and cardiovascular disease.
Journal ArticleDOI
Effect of livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen.
TL;DR: It was concluded that the adding of Livergol to oxaliplatin and irinotecan regimens significantly improved the fatty liver of patients and none of them was superior.
References
More filters
Journal ArticleDOI
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner,Elizabeth M. Brunt,Mark L. Van Natta,Cynthia Behling,Melissa J. Contos,Oscar W. Cummings,Linda D. Ferrell,Yao Chang Liu,Michael Torbenson,Aynur Unalp-Arida,Matthew M. Yeh,Arthur J. McCullough,Arun J. Sanyal +12 more
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
Journal ArticleDOI
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Anna Mae Diehl,Elizabeth M. Brunt,Kenneth Cusi,Michael Charlton,Arun J. Sanyal +7 more
TL;DR: This is a practice guideline for clinicians rather than a review article and interested readers can refer to several comprehensive reviews published recently.
Journal ArticleDOI
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Christi A. Matteoni,Zobair M. Younossi,Terry Gramlich,Navdeep Boparai,Yao Chang Liu,Arthur J. McCullough +5 more
TL;DR: The outcome of cirrhosis and liver-related death is not uniform across the spectrum of nonalcoholic fatty liver, and poor outcomes are more frequent in patients in whom biopsies show ballooning degeneration and Mallory hyaline or fibrosis.
Journal ArticleDOI
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Leon A. Adams,James F. Lymp,Jenny St. Sauver,Schuyler O. Sanderson,Keith D. Lindor,Ariel E. Feldstein,Paul Angulo +6 more
TL;DR: Mortality among community-diagnosed NAFLD patients is higher than the general population and is associated with older age, impaired fasting glucose, and cirrhosis, although the absolute risk is low.
Journal ArticleDOI
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
Giulio Marchesini,Elisabetta Bugianesi,Gabriele Forlani,Fernanda Cerrelli,Marco Lenzi,R. Manini,S. Natale,Ester Vanni,Nicola Villanova,Nazario Melchionda,Mario Rizzetto +10 more
TL;DR: The presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease and the increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades.